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Abstract Tyrosine phosphorylation of Cbl and its association
with signal-transducing molecules in response to macrophage
colony-stimulating factor (M-CSF) were analyzed by using cell
lines which express the wild-type and a mutant M-CSF receptor,
Fms. We found that in a clone, F723 TF-1 cells expressing
mutant Fms in which tyrosine 723 had been substituted with
phenylalanine, the M-CSF stimulation-dependent association
between Cbl and Fms was markedly impaired. However,
phosphorylation of Cbl and its association with the p85 subunit
of phosphatidylinositol 3-kinase were induced in these mutant
cells as seen in the wild-type fms transfectant. These results
suggest that phosphorylation of tyrosine 723 is particularly
important for the recruitment of Cbl to the M-CSF receptor, but
is not required for the phosphorylation and binding of Cbl to
signal-transducing molecules such as p85.
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1. Introduction
Macrophage colony-stimulating factor (M-CSF) is required
for the proliferation, survival, di¡erentiation and activation of
cells of monocyte/macrophage lineage [1,2]. The receptor for
M-CSF (Fms) is encoded by the c-fms proto-oncogene, and
expressed on cells of the monocyte/macrophage lineage in-
cluding osteoclasts and trophoblastic cells [3,4]. The receptor
contains a cytoplasmic tyrosine kinase domain split by the
kinase insert region. M-CSF binding results in the dimeriza-
tion of Fms followed by the activation of its intrinsic tyrosine
kinase [5]. Many cellular proteins, including Fms itself, are
phosphorylated at tyrosine by the activation of Fms. Three
tyrosine autophosphorylation sites have been identi¢ed within
the kinase insert region in human Fms, 699, 708 and 723 [6,7].
When these tyrosines are phosphorylated, a set of signaling
molecules containing Src homology (SH) 2 domains are re-
cruited to these sites, which then activate respective signal
transduction pathways. Grb2 binds to phosphorylated tyro-
sine at 699 [8] and may activate the Ras pathway through
association with the guanine nucleotide exchanging factor,
Sos-1 [9,10]. The p85 subunit of phosphatidylinositol 3-kinase
(PI3-kinase) binds to phosphorylated tyrosine at 723 [7,11],
thereby increasing the catalytic activity of the p110 subunit
[12]. Recent ¢ndings suggested that phospholipase C (PLC)-Q2
also binds to this site [13]. Tyrosine 708 has been suggested to
be the binding site for STAT1 [14]. There are some additional
phosphorylation sites that are important for M-CSF signal-
ing. The phosphorylation of tyrosine 809 is responsible for the
full activation of the tyrosine kinase of Fms or cell surface
expression of Mac2 in response to M-CSF stimulation [15,16].
Tyrosine 809 also functions in the activation of STAT pro-
teins or the induction of c-myc and cyclin D1 mRNAs in
response to M-CSF stimulation [17^19]. Tyrosine 561 is sug-
gested to be the binding site for Src family protein kinases
[20]. Src activation is also important for the M-CSF-depen-
dent induction of c-myc and DNA synthesis [21,22].
The proto-oncogene product Cbl is a 120 kDa protein with
a phosphotyrosine binding (PTB) domain, a RING ¢nger
motif, a highly basic region, a proline rich region (SH3 bind-
ing domain), and a putative leucine zipper motif [23,24]. A
variety of stimulants such as growth factors or interleukins
induce the tyrosine phosphorylation of Cbl which becomes
associated with various proteins containing SH2 and SH3
such as protein tyrosine kinases, p85 subunit of PI3-kinase,
Crk and 14-3-3 [25].
In M-CSF signaling, Cbl was associated with Grb2 in the
unstimulated state, and phosphorylated and membrane-tar-
geted following M-CSF stimulation in the macrophage cell
line, BAC1.2F5 [26]. In this same cell line, Cbl was associated
with p85 after M-CSF stimulation [27]. An association be-
tween Cbl and Fms has been reported in the murine macro-
phage cell line P388 [28]. However, it is not clear how this
molecule can be recruited to the M-CSF receptor. As men-
tioned above, Grb2 and p85 were shown to bind to phos-
phorylated tyrosine at 699 and 723 in Fms respectively. There-
fore, it must be clari¢ed whether these proteins play the role
of adapter between Cbl and Fms, and whether phosphoryla-
tion of these tyrosines is responsible for these interactions or
not.
In this study, we transfected c-fms cDNA into the human
myeloid cell line, TF-1, and established cell lines overexpress-
ing wild-type or a series of tyrosine-phenylalanine mutants of
Fms by which association of p85 and Grb2 with Fms was
impaired. By using these clones, we analyzed behaviors of
Cbl such as tyrosine phosphorylation and its association
with Fms and p85 upon M-CSF stimulation.
2. Materials and methods
2.1. Cells
To obtain bone marrow macrophages, the precursor cells in bone
marrow of 8-week-old male C57BL/6 mice were cultured for 5 days
0014-5793 / 00 / $20.00 ß 2000 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 9 ) 0 1 7 6 7 - 6
*Corresponding author. Fax: (81)-429-96 5202.
FEBS 23192 14-1-00
FEBS 23192FEBS Letters 466 (2000) 96^100
with RPMI 1640 medium supplemented with 10% fetal calf serum
(Hyclone Laboratories, Logan, UT, USA) and with 100 ng/ml of
human recombinant M-CSF [29]. Then, adherent cells were recovered
and used for experiments.
c-fms expression plasmids were constructed and transfected into the
human erythroleukemic cell line TF-1 [30] as follows: elongation fac-
tor promoter was separated from pEF-BOS [31] and introduced into
the expression vector pRcCMV (Invitrogen, San Diego, CA, USA).
Human c-fms gene (kindly provided by Dr. C.J. Sherr) was inserted
downstream of the elongation factor promoter in this plasmid. We
substituted each tyrosine at 561, 699, 723 and 809 with phenylalanine
in Fms by means of PCR-based site-directed mutagenesis as described
[32]. The following oligonucleotides were used as PCR mutation
primers: 5P-TGAGGGCAACAGTTTTACTT-3P, 5P-CGTCGACTT-
TAAGAACA-3P, 5P-GGACACCTTTGTGGAGA-3P and 5P-CTC-
CAACTTCATTGTCA-3P for 561, 699, 723 and 809, respectively.
The mutation was veri¢ed by DNA sequencing. The expression plas-
mids were transfected into TF-1 using Lipofectin methods (Gibco
BRL, Grand Island, NY, USA). Cells were selected in G418 (Genet-
icin, Gibco BRL) to establish cell lines. Clones expressing high levels
of the gene were selected by means of £ow cytometry using an anti-c-
fms antibody (Ab2, Oncogene Science, Uniondale, NY, USA). The
transfectant of vector alone in TF-1 cells (MOCK) and stable TF-1
cell lines over-expressing wild-type (WT) or mutant (F561, F699, F723
and F809) human Fms were maintained in RPMI 1640 medium sup-
plemented with 10% fetal calf serum (Hyclone Laboratories) and with
5 ng/ml of human recombinant GM-CSF (kindly provided by the
Kirin Brewery, Tokyo, Japan).
2.2. Immunoprecipitation and immunoblotting
Cells were serum-starved for 4 h, then left untreated or stimulated
for 3 min at 37‡C with M-CSF (100 ng/ml). The cells were lysed in ice-
cold TNE (10 mM Tris^HCl pH 7.8, 150 mM NaCl, 1 mM EDTA,
0.1% Nonidet P-40, 20 mg/ml aprotinin, 2 mM Na3VO4). Cell lysates
were pre-cleared with protein G-Sepharose (Sigma, St. Louis, MO,
USA) for 1 h, then incubated with the appropriate antibodies for
4 h at 4‡C. The immunocomplexes were recovered with protein G-
Sepharose and washed with TNE lysis bu¡er. The precipitates were
separated by 8% acrylamide SDS-polyacrylamide gel electrophoresis
(PAGE) and transferred to a PVDF membrane (Immobilon, Milli-
pore, Bedford, MA, USA). The membrane was immunoblotted with
appropriate antibodies, then visualized by enhanced chemilumines-
cence (Dupont NEN, Boston, MA, USA). Anti-phosphotyrosine
(4G10), anti-Fms and anti-p85 subunit of PI3-kinase antibodies
were obtained from UBI (Lake Placid, NY, USA). Anti-Cbl (C-15),
anti-CrkL (C-20) and anti-GST (B-14) antibodies were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-Fms anti-
body (Ab2, Oncogene Science) was used for immunoprecipitation.
Anti-Cbl antibody (Transduction Laboratory, Lexington, KY, USA)
was used for immunoblotting.
3. Results
3.1. p120Cbl is one of the major substrates of tyrosine kinase
activated by M-CSF stimulation
Bone marrow-derived macrophages were stimulated by M-
CSF and the tyrosine-phosphorylated proteins were analyzed
by immunoblotting with anti-phosphotyrosine antibody. As
reported previously [28], Cbl was identi¢ed as one of the
prominent substrates of the tyrosine kinase activated by M-
CSF stimulation (Fig. 1A). In an M-CSF-dependent cell line,
TF-1/fms, which overexpresses functional Fms proteins on
transfection of c-fms cDNA in TF-1, we obtained the same
results as described above (Fig. 1B). The time courses of
phosphorylation after M-CSF stimulation were similar be-
tween Cbl and Fms.
3.2. The phosphorylation of tyrosine 723 is important for the
association of Cbl with Fms
For the analysis of the Cbl phosphorylation and signal
transduction pathways of Cbl, we established a series of TF-
1 sublines that expressed mutant Fms. The mutations were
tyrosine (Y)-phenylalanine (F) substitutions of Y561, Y699,
Y723 and Y809 in Fms.
Prior to analyzing the phosphorylation and association, we
veri¢ed that all transfectants express the same amount of Fms
proteins by £ow cytometric analysis (data not shown) and
immunoblotting (Fig. 2A). We also con¢rmed that the pre-
dicted associations of signaling molecules with Fms were ab-
rogated by the introduction of mutation. In the clone F561,
the M-CSF-dependent association between one of the Src
Fig. 1. Tyrosine phosphorylation of Cbl in bone marrow macrophages and TF-1/fms cells upon M-CSF stimulation. The total cell lysates and
immunoprecipitates of anti-Cbl antibody of quiescent or M-CSF-stimulated bone marrow macrophages were separated by 8% SDS-PAGE
under reducing conditions, then immunoblotted with anti-phosphotyrosine antibody. Molecular weight standards (pre-stained markers, Bio-
Rad) are on the left (A). Results of the same experiments using TF-1/fms cells are shown in the left panel of B. TF-1/fms cells were lysed at
the indicated times after M-CSF stimulation, immunoprecipitated with anti-Cbl or anti-Fms antibodies and immunoblotted with anti-phospho-
tyrosine, anti-Cbl, or anti-Fms antibodies (right panel in B).
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family proteins, Lyn, and Fms was abrogated (data not
shown). Unexpectedly, the association between Grb2 and
Fms was not completely abrogated in clone F699 [20] (data
not shown), unlike in a previous study using a ¢broblast cell
line [8]. In hematopoietic cell lines such as TF-1, it is di⁄cult
to obtain clear cut results of association particularly in the
case of small adapter molecules like Grb2, because they indi-
rectly associate with Fms via binding to other signaling mol-
ecules such as Shc, which is known to associate with Fms. In
clone F723, the association between p85 and Fms was com-
pletely abrogated [7] (data not shown).
Cbl was immunoprecipitated by anti-Cbl antibody and im-
munoblotted with anti-phosphotyrosine or anti-Cbl antibod-
ies. The phosphorylation of Cbl was induced in all mutant
Fms-expressing clones as in wild-type clones (Fig. 2B). The
relative levels of Cbl phosphorylation were 100, 54, 34, 28 and
55 in WT, F561, F699, F723 and F809 clones, respectively,
when the intensities of phosphorylated Cbl were normalized
with the amount of immunoprecipitated Cbl proteins. The
di¡erences in the quantities of Cbl protein in Fig. 2B were
not due to a change in the expression levels of Cbl proteins on
the transfection of various mutant c-fms constructs. Although
the level of phosphorylation of Cbl was decreased in the mu-
tant Fms-expressing clones, especially in F699 and F723, its
phosphorylation was not completely abrogated by any of the
mutations examined (Fig. 2B). We have con¢rmed these re-
sults by using three independent clones. Next, we compared
the amount of phosphorylated protein with a molecular
weight of about 150 kDa that was co-precipitated with Cbl
(arrowhead in Fig. 2B). The 150 kDa protein signals did not
appear in clone F723 (mutation in the p85 and PLC-Q2 bind-
ing sites) and appeared weakly in clone F699 (mutation in the
Grb2 binding site) when compared with that of wild-type,
F561 and F809 (Fig. 2B). As p165Fms is a tyrosine-phosphory-
lated protein, we investigated whether the 150 kDa Cbl-asso-
ciated protein was Fms or not. As shown in Fig. 2C, Cbl was
found in the anti-Fms immunocomplexes in WT cells and vice
versa. However, no association between Cbl and Fms in F723
cells was observed (Fig. 2C, lower panel). These results show
that Cbl associates with Fms by M-CSF stimulation, and
phosphorylation of tyrosine 723 is particularly important for
the association of Cbl with Fms. When the immunopresipi-
tates of anti-Fms antibody were blotted with anti-phosphotyr-
osine antibody, a 120 kDa protein, which was likely a phos-
phorylated Cbl, was observed in the wild-type, but not
detected in clone F723 (Fig. 2D, left panel). Conversely, a
phosphorylated protein was present at the same position as
p165Fms in immunoprecipitate of anti-Cbl antibody in the
wild-type cells, but was absent in the F723 cells (Fig. 2D,
right panel). The results also indicated that the tyrosine phos-
phorylation of Cbl occurred to a certain degree upon stimu-
lation by M-CSF irrespective of an association with Fms.
Fig. 2. Tyrosine phosphorylation of Cbl and its association with Fms in the wild-type (WT) or mutant c-fms-transfected TF-1 cells by M-CSF
stimulation. Total cell lysates of MOCK, WT, and mutant Fms-expressing TF-1 cells were immunoblotted with anti-Fms antibody (A). Cells
expressing WT and mutant Fms were either unstimulated or stimulated with M-CSF and their lysates were immunoprecipitated with anti-Cbl
antibody. The precipitates were separated as described in Fig. 1A and immunoblotted with anti-phosphotyrosine or anti-Cbl antibodies. The ar-
rowhead points to the protein with a molecular weight of about 150 kDa that was coprecipitated with Cbl (B). TF-1 cells expressing WT
(upper panel) and F723 (lower panel) Fms were incubated in the absence or presence of M-CSF, then lysed and immunoprecipitated with anti-
Fms or anti-Cbl antibodies. The precipitates were separated as described in Fig. 1A and immunoblotted with anti-Fms or anti-Cbl antibodies
(C). The same samples as C were immunoblotted with anti-phosphotyrosine antibody. Molecular weight standards (pre-stained markers, Bio-
Rad) are on the left (D).
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3.3. M-CSF stimulation-dependent association of Cbl with the
p85 subunit of PI3-kinase was not impaired by F723 and
other mutations
Recent ¢ndings revealed that membrane localization of PI3-
kinase is necessary for alteration of the cytoskeleton in macro-
phages, and this requires the ligand stimulation-dependent
association between Cbl and the p85 subunit of the PI3-kinase
[33]. We therefore examined the association of Cbl with p85
upon M-CSF stimulation of TF-1/fms cells. Immunoprecipi-
tation using anti-Cbl antibody followed by immunoblotting
with the anti-p85 antibody revealed that the p85 subunit
was co-precipitated with Cbl in an M-CSF-dependent manner
in the wild-type and the mutant fms transfectants including
cell line F723 (Fig. 3), in which Cbl was tyrosine-phosphory-
lated upon M-CSF stimulation but did not associate with
Fms, as shown in Fig. 2B. These results indicate that M-
CSF induces the association of Cbl with p85 in vivo, irrespec-
tive of the association of both p85 and Cbl with Fms.
4. Discussion
In this study, we analyzed the tyrosine phosphorylation of
Cbl and association with Fms and other signal-transducing
molecules upon M-CSF stimulation using various cell clones
that express a series of tyrosine-phenylalanine-substituted
Fms. In our system, the substitution of 723 resulted in marked
impairment of the Cbl-Fms association (Fig. 2). However, it
should be mentioned that Cbl was phosphorylated at its ty-
rosine, although to a lesser extent (Fig. 2B), and associated
with p85 (Fig. 3) upon M-CSF stimulation in the mutant cells
with Y723F substitution. The abrogation of the association
between Cbl and Fms in clone F723 was not due to the de-
creased phosphorylation of Cbl, because the association was
not detectable in F723 even when the same amount of phos-
phorylated Cbl compared to that in wild-type was precipitated
(Fig. 2D, right panel). These results indicate that the phos-
phorylation of Cbl and its association with p85 do not com-
pletely depend on the association of the Cbl with activated
Fms and suggest that a part of Cbl is phosphorylated by a
tyrosine kinase other than Fms.
Tyrosine phosphorylation of Cbl is a common event in
growth factor and cytokine signaling. Previous works have
revealed that Src is responsible for Cbl phosphorylation in
osteoclasts using src-de¢cient mice, and Cbl phosphorylation
was impaired in B cells and T cells by targeting disruption of
lyn and fyn, respectively [34,35]. In peritoneal macrophages, a
triple mutation of hck3=3, fgr3=3 and lyn3=3 but not a single
mutation of each impaired the phosphorylation of Cbl in
response to integrin-mediated adhesion [33]. These studies
provide evidence that Src family kinases are responsible for
Cbl phosphorylation in many systems. In M-CSF signaling,
however, the mutation of Y561 (possible binding site for Src
family kinases) did not impair the phosphorylation of Cbl
(Fig. 2), suggesting that a kinase other than the Src family
kinases played a role in this phosphorylation. We observed a
di¡erence in the phosphorylation pattern of cellular proteins
between the wild-type and F561 mutant: this mutation abro-
gated tyrosine phosphorylation of STAT3, but not of Tyk2
(data not shown). Therefore, the phosphorylation of Cbl
might be dependent on kinases activated by Fms such as
Tyk2.
Tyrosine 723 was originally identi¢ed as the docking site for
p85 [7,11]. Recently, it was indicated that PLC-Q2 also binds
to the phosphorylated Y723 as p85 does [13]. PLC-Q2 is a 150
kDa protein with SH2 and SH3 domains that was reported to
bind to Cbl via its SH2 domain in in vitro experiments using
Jurkat cells [36]. In our in vivo immunoprecipitation experi-
ments, M-CSF stimulation did not induce an association of
Cbl with PLC-Q2 (data not shown), suggesting that the bind-
ing of Cbl to Y723 was not mediated by PLC-Q2. While p85
associates both with Fms and Cbl, it remains unde¢ned
whether Cbl associates indirectly with phosphorylated Y723
via binding to p85. Notably, two of the phosphorylation sites
in Cbl contain the phosphotyrosine containing motif, pTyr-X-
X-Met (pY371 and pY731), that is compatible with the bind-
ing preference of both N-terminal and C-terminal SH2 do-
mains of p85 [37]. It should also be noted that there are
two such motifs in activated M-CSF receptor dimer at
pY723. It is not clear, however, whether two SH2 domains
of p85 bind to the same molecule (Cbl or Fms), or two dis-
tinct molecules (Cbl and Fms). We observed that the associ-
ation of Cbl with Fms was considerably impaired by the mu-
tation of tyrosine 699 (Fig. 2), suggesting that Grb2 also
participates in the Cbl-Fms interaction. However, this tyro-
sine seems to be less important for these interactions than
tyrosine 723.
Cbl associates with some growth factor receptors, including
EGF and PDGF receptors, directly via its PTB domain
[38,39]. The predicted amino acid sequence of the PTB bind-
ing motif was Asp-Asp/Glu-X-pTyr [40]. Although there is no
such consensus sequence in the cytoplasmic region of Fms, it
is notable that the sequence surrounding Y723 is Val-Asp-
Thr-Tyr. The Asp at the 32 position of Tyr was found to
be important for recognition by the Cbl-PTB domain [40]. We
therefore could not exclude the possibility that Cbl associates
with Fms directly via its PTB domain.
One of the physiological functions of Cbl is thought to be
the regulation of the cytoskeleton, which is required to exhibit
di¡erentiation speci¢c functions such as bone remodeling of
osteoclasts or migration of peritoneal macrophages [33,34].
Another function of Cbl, which is suspected in Caenorhabditis
elegans, Drosophila and mammals, is negative regulation of
receptor tyrosine kinase [41^43]. One mechanism in the neg-
ative regulatory function is demonstrated in mast cell and T
cell signalings. In these cells, Cbl interacts with Syk and ZAP-
70 in response to immunoglobulin receptor and T cell receptor
engagement, respectively, and inhibits the activity of these
tyrosine kinases [24,44]. However, the physiological functions
of Cbl in the M-CSF signal cascade have not been elucidated.
The phosphorylation of Cbl is important for its association
Fig. 3. M-CSF-dependent association of Cbl with p85 in wild-type
(WT) or mutant c-fms-transfected TF-1 cells by M-CSF stimulation.
The TF-1 cells expressing WT and mutant Fms were incubated in
the absence or presence of M-CSF, then lysed and immunoprecipi-
tated with anti-Cbl antibody. The precipitates were separated as de-
scribed in Fig. 1A and immunoblotted with anti-p85 or anti-Cbl
antibodies.
FEBS 23192 14-1-00
J. Ota et al./FEBS Letters 466 (2000) 96^100 99
with p85 (Fig. 3). Therefore, the identi¢cation of the tyrosine
kinase(s) that physiologically phosphorylate(s) Cbl is required
to understand the role of Cbl in M-CSF signaling.
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